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Yclopidogrel-treated patients undergoing emergent or elective PCI for stable angina or
acute coronary syndrome (non-ST-elevation and ST-elevation myocardial infarction,
unstable angina). The main outcome measures were cardiovascular (CV) death, def-
inite/probable stent thrombosis (ST), nonfatal myocardial infarction (MI), coronary
revascularization (PCI or CABG) and a composite end point of ischemic events. High
platelet reactivity (HPR) was deﬁned as PRU (P2Y12 Reaction Unit) value  240 or 252.
RESULTS In total, 1038 consecutive patients were enrolled (Male 749, 72.7%). Pa-
tients with HPR were 487 (46.9%). VerifyNow P2Y12 cartridge was used in 1038 pa-
tients. All patients received optimal clopidogrel pretreatment and maintenance
therapy. At a 12-month follow-up, we found 85 ischemic events (18 CV deaths [1.7%],
7 nonfatal MIs [0.7%]), 5 stent thrombosis (0.5%) and 47 target-vessel re-
vascularizations (4.5%). The CV rate of patients with HPR (PRU > 240) was signiﬁ-
cantly higher rate (2.7% vs 1.0% (p ¼ 0.030)) than the patients with normal value. The
composite end point event rate of patients with HPR (PRU > 240) was also signiﬁ-
cantly higher rate (8.07% vs 4.5% (p ¼ 0.020)) than the patients with normal value. In
survival analysis, there was no signiﬁcant difference between patient with HPR (PRU
> 240) and normal reactivity. But between patient with HPR (PRU > 252, cutoff value
of CILON-T trial) and normal reactivity, the survival rate free from the CV death was
signiﬁcantly lower in patients with high on-treatment platelet reactivity(p ¼ 0.037,
Log Rank test).
CONCLUSION HPR tested by VerifyNow predict coronary adverse event in patients
after PCI. In Korean, the rate of HPR was higher than western people and we seem to
have to raise the optimal cutoff value of PRU to predict future coronary event in
Korean.
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Assessment Of Impact Of Chronic Kidney Disease On Platelet Inhibition Among
Post Percutaneous Intervention Patients On Antiplatelet Therapy
Maddury Jyotsna, Ashok Kumar Arigondam, Siva Krishna Venkata
Nizam’s institute of medical sciences, Secunderabad, India
BACKGROUND CKD may inﬂuence the response to antiplatelet therapy. We, there-
fore, sought to investigate its effect on platelet inhibition according to its stages.
METHODS We assessed platelet inhibition (PI) among those patients on dual anti-
platelet regimen (75 mg of Aspirin and 75 mg of clopidogrel) in various stages of CKD
in 922 patients after PCI with stent implantation. Platelet inhibition was tested with
platelet aggregometry. Effective PI is deﬁned as > 50% platelet inhibition. CKD was
deﬁned as a estimated glomerular ﬁltration rate (eGFR) <60 mL/min/1.73 m2 . eGFR
was estimated by MDRD formula. We analyzed PI levels with eGFR values using
Pearson correlation test.
RESULTS Total no of cases are 922. Male:female::3.4:1. 606 (66%) were hyperten-
sives, 417 (45%) were diabetics and 224 (24%) were smokers. 548 (59%) pts were
presented with ACS and multi vessel angioplasty was done in 214 (23%) patients.
Total no of lesions treated were 1225 in 922 pts . Prevalence of patients according
to stages of CKD were - Stage 1 - 209(23%); Stage 2 - 415 45(%);Stage 3a - 158 (17%);
Stage 3b - 104 (11%); Stage 4 - 15 (1.6%); Stage 5 - 19(2%) pts. There was no correlation
between estimated GFR and percentage of inhibition of platelets in all pts (Pearson
correlation ¼ -0.021; p Value ¼ 0.7) and in different stages CKD pts (Stage 1 -
Pearson correlation ¼ -0.039, p value ¼ 0.8, Stage 2 - correlation ¼ -0.008, p ¼ 0.9,
Stage 3a correlation ¼ -0.002, p ¼ 0.98, Stage 3b correlation ¼ 0.052, p ¼ 0.8, Stage 4
correlation ¼ 0.9, p ¼ 0.1 and Stage 5 correlation ¼ -0.6, p ¼ 0.3) .
CONCLUSION Presence of CKD (including the all stages) does not inﬂuence the
effectiveness of platelet inhibition with antiplatelet therapy in pts undergoing PCI for
obstructive CAD.ATHERECTOMY DEVICES
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Safety of Rotational Atherectomy in High Risk PCI with Hemodynamic Support
Soha Ahmad, Han Tun, Michael Gaglia, Anilkumar Mehra, Ray V. Matthews,
David M. Shavelle, Leonardo Clavijo
University of Southern California, Los Angeles, CA
BACKGROUND Rotational atherectomy (RA) can aid in high risk Percutaneous Coro-
nary Intervention (PCI) with hemodynamic support. There is concern that use of RA
could result in increased procedural complications. We report our institution’s
experience with RA in high risk PCI with hemodynamic support.
METHODS 398 patients underwent high risk PCI with intraaortic balloon pump (IABP)
(n¼327), Impella (n¼57), or Tandem Heart (n¼14) between 2008 and July 2014.
Patients with ST elevated myocardial infarction were excluded (n¼129). Patients who
underwent RA (n¼34) were compared to those who did not (n¼235). Among the 34
patients who underwent RA, Impella use (n¼10) versus IABP use (n¼23) was
compared.
RESULTS Patients in the RA arm were older (71.9114.47 vs. 64.7712.63, p¼0.003)
and less likely in cardiogenic shock (6% vs. 23%, p¼0.02). There was no difference inthe number of diseased vessels (RA¼ 2.860.88 vs. no RA ¼2.680.99, p¼NS),
location of vessels, or number of total occlusions (RA ¼ 32% vs. no RA ¼32%, p¼NS).
PCI without stent deployment was less common in the RA arm (15% vs. 37%, p¼0.01).
There was no difference in stent diameter or length. There was a trend toward more
Impella use, but this was not statistically different (RA ¼ 29% vs. no RA ¼18%, p¼NS).
There was no difference in morbidity, hospital mortality, recurrent MI, or repeat
revascularization. Within the rotational atherectomy group, there was no difference
in outcome between IABP or Impella 2.5.
CONCLUSION In our center’s experience, use of rotational atherectomy in high risk
PCI with hemodynamic support is feasible and not associated with increased
morbidity or mortality.CRT-129
One-year Safety Outcomes In Diabetic Patients Treated With Orbital
Atherectomy For De Novo, Severely Calciﬁed Coronary Lesions: A Sub-analysis
Of The ORBIT II Trial
Jeffrey W. Chambers,1 Arthur C. Lee2
1Metropolitan Heart and Vascular Institute, Minneapolis, MN; 2The Cardiac and
Vascular Institute, Gainesville, FL
BACKGROUND Patients with diabetes mellitus (DM) are at increased risk for severe
coronary artery calciﬁcation. Severely calciﬁed lesions make successful balloon an-
gioplasty and stent delivery more difﬁcult during percutaneous coronary interven-
tion (PCI) and treatment may lead to serious procedural complications. Compared to
non-diabetics, diabetics have increased incidence of major adverse cardiac events
(MACE) after PCI. In this analysis, we compared 1-year safety outcomes in ORBIT II
patients with or without DM treated with the Diamondback 360 Coronary Orbital
Atherectomy System (OAS) (Cardiovascular Systems, Inc., St. Paul, MN).
METHODS ORBIT II, a prospective, multi-center trial conducted in the US, was
designed to evaluate the safety and efﬁcacy of the Diamondback 360 Coronary OAS to
prepare de novo, severely calciﬁed coronary lesions for stent deployment. Freedom
from 1-year MACE (deﬁned as cardiac death, myocardial infarction (MI, CK-MB>3X
ULN), and target vessel revascularization (TVR)) was compared in patients with his-
tory of DM (DM group, N¼160) versus patients without history of DM (no-DM group,
N¼283).
RESULTS Patients in the DM group were younger (70.3  0.7 vs 72.0  0.6, p¼0.02),
had higher BMI (31.0  0.5 vs 28.5  0.3, p<0.0001), higher prevalence of hyperten-
sion (96.3% vs 89.0%, p¼0.01), and higher rate of previous coronary artery bypass
graft (20.0% vs 11.7%, p¼0.02). As estimated by Kaplan-Meier, at one one-year both
DM and non-DM patients had similar high freedom from MACE (83.5% vs 83.6%,
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Yp¼0.98), cardiac death (96.8% vs 97.1%, p¼0.84), MI (91.9% vs 89.4%, p¼0.40), Q-
wave MI (100.0% vs 98.6%, p¼1.0), non-Q-wave MI (91.9% vs 90.8%, p¼0.70), and
TVR (94.1% vs 94.2%, p¼0.98).
CONCLUSION Using the OAS as a lesion preparation tool prior to stent deployment in
both diabetics and non-diabetics may offer patients with severely calciﬁed coronary
lesions a new treatment option, with low rates of MACE at one-year post-procedure.
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Orbital Atherectomy Treatment of Severely Calciﬁed Coronary Lesions in
Patients with History of Coronary Artery Bypass Grafting: One Year Safety
Outcomes from the ORBIT II Trial
Jeffrey W. Chambers,1 Arthur C. Lee2
1Metropolitan Heart and Vascular Institute, Minneapolis, MN; 2The Cardiac and
Vascular Institute, Gainesville, FL
BACKGROUND History of prior coronary artery bypass grafting (CABG) may be asso-
ciated with increased incidence of major adverse cardiac events (MACE) in patients
undergoing repeat CABG, percutaneous coronary intervention, or medical treatment.
In this analysis, one year safety outcomes were evaluated in patients with and
without history of CABG treated with orbital atherectomy for de novo, severely
calciﬁed coronary lesions.
METHODS ORBIT II, a prospective, multicenter, non-blinded trial, enrolled 443 pa-
tients with severely calciﬁed coronary lesions. Orbital atherectomy was used to
modify lesions for stent placement. One year safety outcomes were compared in
patients with and without history of CABG (N¼65 and N¼378).
RESULTS ORBIT II patients with history of CABG were more likely to be male and have
a higher prevalence of diabetes, history of dyslipidemia, hypertension, and myocar-
dial infarction (MI). One year safety outcomes are presented in Table I. The higher rate
of in-hospital MACE (16.9% vs. 8.5%, p¼0.04) in the prior CABG group was likely
driven by the higher rate of non-Q-wave MI (15.4% vs. 7.5%, p¼0.05). At one year,
however, using multivariate analysis prior CABG was not associated with increased
MACE (HR 0.57, p¼0.08) after adjusting for baseline and pre-procedural factors.
CONCLUSION Preparation of severely calciﬁed coronary lesions with orbital athe-
rectomy facilitated stent delivery in patients with a history of CABG, resulting in low
rates of 1-year MACE, MI, cardiac death, and target vessel revascularization.
Table I. ORBIT II Safety Outcomes Through 1-Year Follow-upPrior CABG No Prior CABG p-value1-yearMACE (%) 26.3 14.7 0.02Cardiac death (%) 4.7 2.7 0.41Q-wave MI (%) 1.5 0.8 0.57Non-Q-wave MI (CK-MB>3XULN) (%) 15.4 7.7 0.05TVR (%) 8.0 5.5 0.45CRT-131
First- Versus Second-generation Drug-eluting Stents Following Rotational
Atherectomy In Patients With Heavily Calciﬁed Coronary Lesions
Wenjie Tian, Rebecca Torguson, Marco De Magalhaes Pereira, Thibault Lhermusier,
Hideaki Ota, Nevin Baker, Sarkis Kiramijyan, Eddie Koifman, Smita Negi,
Ron Waksman
MedStar Washington Hospital Center, Washington, DC
BACKGROUND Little information is available regarding the comparison between the
ﬁrst- and second-generation drug-eluting stents (DES) following rotational athere-
cotmy (ROTA) for patients with heavily calciﬁed coronary lesions (HCCL).
METHODS Ninety-nine patients with HCCL who underwent RA prior to ﬁrst-genera-
tion DES (n¼40, 53 lesions) or second-generation DES (n¼59, 63 lesions) implantation
were retrospectively analyzed. The primary endpoint was the rate of major adverse
cardiac events (MACE).
RESULTS Baseline clinical and procedural characteristics were similar between the
two groups, except for more complex type C lesions (81.0% vs. 58.8%, p¼0.01) and
more proportion of post dilation (52.4% vs. 23.1%, p¼0.001) in the second-generation
DES group. The procedure success rate was similar in the two groups (95% vs. 100%,
p¼0.161). Compared with ﬁrst-generation DES group, there were no differences
regarding the occurrence of MACE (11.9% vs. 12.8%, p¼1.000), TLR (3.6% vs. 2.7%,
p¼1.000) and all-cause death (8.5% vs. 10.3%, p¼1.000) in the second-generation DES
group at 1-year follow-up. No stent thrombosis was found in all patients.
CONCLUSIONS The ﬁrst- and second-generation DES following ROTA resulted in
comparable outcomes in patients with HCCL at 1 year follow-up.Table I. In-hospital, 6-month and 1-year clinical outcomesVariable1-st generation DES
(n[40, 53 lesions)2-nd generation DES
(n[59, 63 lesions) p- valueIn-hospital MACE (%) 5.0 0 0.1616 month follow-up (%)MACE 7.5 6.8 1.000All cause death 5.0 5.1 1.000Cardiac death 0 5.1 0.274Q-wave MI 0 0 _TLR 2.5 1.7 1.000Stent thrombosis 0 0 _1 year follow-up (%)MACE 12.8 11.9 1.000All cause death 10.3 8.5 1.000Cardiac death 0 8.5 0.153Q-wave MI 0 0 _TLR 2.7 3.6 1.000Stent thrombosis 0 0 _MACE: Major adverse cardiac events; MI: Myocardial infarction; TLR: Target lesion revascularizationCRT-132
Clinical Outcomes Comparison Among Different Strategies Of Lesion Preparation
For Heavily Calciﬁed Coronary Lesions With Drug-eluting Stents Implantation:
Plain Balloon, Cutting Balloon And Rotational Atherectomy
Wenjie Tian, Rebecca Torguson, Nevin Baker, Thibault Lhermusier, Hideaki Ota,
Sarkis Kiramijyan, Smita Negi, Eddie Koifman
MedStar Washington Hospital Center, Washington, DC
BACKGROUND This study aimed to compare the outcome following plain old balloon
angioplasty (POBA), cutting balloon angioplasty (CBA) and rotational atherectomy
(ROTA) in patients with heavily calciﬁed coronary lesions (HCCL).
METHODS Clinical data of the patients with HCCL who underwent POBA (n¼220),
CBA (n¼253), or ROTA (n¼264) prior to DES implantation from 2003-2013 were
retrospectively analyzed. The occurrence of major adverse cardiac events (MACE),
deﬁned as all-cause death, myocardial infarction (MI) or target lesion revasculariza-
tion (TLR) were compared at one year follow-up.
RESULTS Baseline clinical characteristics were similar among the three groups,
except for older patients age, and type C lesions in the ROTA versus the CBA and
POBA (71.910.4 vs. 68.010.8, 68.711.8 years, p<0.001), and (61.7% vs. 35.8%,
45.0%, p<0.001) respectively. Angiographic success was achieved in all patients. At
one year follow-up, the MACE rate was similar (14.6% in the ROTA group, 12.3% in the
POBA group and 8.3% in the CBA group, p¼0.204). The occurrence of stent throm-
bosis was 0.6% in the CBA and 0% in the ROTA and POBA group.
CONCLUSIONS In patients with HCCL, ROTA was frequently used for the treatment of
more complex lesions compared with CBA and POBA. The different strategies with
ROTA, CBA and POBA prior to DES implantation resulted in the similar long-term
outcomes after optimal lesion preparation for patients with HCCL.Table I. 6-month and 1-year clinical outcomesVariable POBA (n[220) CBA (n[253) ROTA (n[264) p value6 month follow-up (%)MACE 9.2 3.9 8.6 0.118All cause death 6.2 2.2 6.3 0.135Cardiac death 1.6 1.1 1.8 0.897Q-wave MI 0 0 0 -TLR 2.4 2.3 2.4 1.00Stent thrombosis 0 0.5 0 1.001 year follow-up (%)MACE 12.3 8.3 14.6 0.204All cause death 8.2 4.5 9.8 0.178Cardiac death 2.5 1.3 3.1 0.611Q-wave MI 0 0.7 0 1.00TLR 3.5 3.9 5.2 0.765Stent thrombosis 0 0.6 0 0.629MACE: Major adverse cardiac events; MI: Myocardial infarction; TLR: Target lesion revascularization
